» Articles » PMID: 38543908

Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases

Overview
Date 2024 Mar 28
PMID 38543908
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus disease 2019 (COVID-19) vaccination is essential for patients with autoimmune inflammatory rheumatic diseases (AIIRD) to reduce the risk of morbidity and mortality associated with serious COVID-19 infection. With endemicity, waning of vaccine- and infection-acquired immunity, and development of SARS-CoV-2 variants, the need for additional doses of vaccines against serious illness in high-risk immunocompromised persons remains imperative. This review examines how immunomodulatory therapies affect vaccine-induced immune response in patients with AIIRD. Glucocorticoids, methotrexate, azathioprine, calcineurin inhibitors, mycophenolate mofetil, tumor necrosis factor inhibitors, and abatacept have been shown to variably attenuate both humoral and cellular immune responses to vaccination. Janus kinase inhibitors reduce humoral immune response. In contrast, sulfasalazine, leflunomide, belimumab, interleukin (IL)-17, IL-12/23, IL-6, and IL-1 inhibitors appear favorable, with mild or no impact on vaccine response. Although rituximab is known to profoundly diminish humoral immune response, cellular immunity is relatively preserved. Administering a third and subsequent vaccine dose or temporally coordinating the dosing of immunomodulatory drugs may improve vaccine effectiveness. Further research is needed to personalise vaccination strategies for AIIRD patients, considering their specific immunomodulatory treatments.

Citing Articles

Special Issue: "Vaccination and Global Health".

Ma S, Bi Q, Liu L, Thapa R, Li W, Liu B Vaccines (Basel). 2024; 12(11).

PMID: 39591126 PMC: 11598834. DOI: 10.3390/vaccines12111223.


Prophylactic and therapeutic vaccine development: advancements and challenges.

Weerarathna I, Doelakeh E, Kiwanuka L, Kumar P, Arora S Mol Biomed. 2024; 5(1):57.

PMID: 39527305 PMC: 11554974. DOI: 10.1186/s43556-024-00222-x.


Endurance Exercise Does Not Exacerbate Cardiac Inflammation in BALB/c Mice Following mRNA COVID-19 Vaccination.

Eens S, Van Hecke M, Van den Bogaert S, Favere K, Cools N, Fransen E Vaccines (Basel). 2024; 12(9).

PMID: 39339998 PMC: 11435831. DOI: 10.3390/vaccines12090966.

References
1.
Yang L, Costales C, Ramanathan M, Bulterys P, Murugesan K, Schroers-Martin J . Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study. J Clin Virol. 2022; 153:105217. PMC: 9188451. DOI: 10.1016/j.jcv.2022.105217. View

2.
Smetanova J, Strizova Z, Sediva A, Milota T, Horvath R . Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab. Lancet Rheumatol. 2021; 4(3):e163-e166. PMC: 8691856. DOI: 10.1016/S2665-9913(21)00393-3. View

3.
Wieske L, van Dam K, Steenhuis M, Stalman E, Kummer L, van Kempen Z . Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022; 4(5):e338-e350. PMC: 8930018. DOI: 10.1016/S2665-9913(22)00034-0. View

4.
Boedecker-Lips S, Classen P, Kraus D, Weinmann-Menke J . Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus. Rheumatology (Oxford). 2022; 62(3):e34-e35. PMC: 9384795. DOI: 10.1093/rheumatology/keac459. View

5.
Xu C, Yi Z, Cai R, Chen R, Thong B, Mu R . Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. Autoimmun Rev. 2021; 20(4):102778. PMC: 7889462. DOI: 10.1016/j.autrev.2021.102778. View